Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Conditions: X-Linked Hypophosphatemia
Interventions: burosumab, Oral Phosphate Supplement, active vitamin D; Biological · Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Sebum Production, Stool Microbiome, Transepidermal Water Loss, Facial Brrightness, Erythema, Wrinkles, Facial Shine
Interventions: Placebo Oral Tablet, Rubia Cordifolia, Triphala; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
Interventions: Cohort A1, Cohort A2, Cohort A3, A3 Expansion, Cohort B1, Cohort B2, Cohort B3, B3 Expansion; Drug
Lead sponsor: Rebecca Arend; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Calcium Phosphate Kidney Stones
Interventions: OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose; Dietary Supplement · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dental Caries
Interventions: Inactive supplement, Tricalcium phosphate supplement, Calcium carbonate supplement, Calcium citrate supplement, Inactive supplement and fluoride mouthwash, Calcium carbonate supplement and fluoride mouthwash, Calcium citrate supplement and fluoride mouthwash; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections
Interventions: Vitamin D supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Hematologic Malignancy, Myeloid Malignancy
Interventions: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.